Melanoma in situ of right lower eyelid, including canthus
ICD-10 D03.112 is a billable code used to indicate a diagnosis of melanoma in situ of right lower eyelid, including canthus.
Melanoma in situ of the right lower eyelid, including the canthus, is a localized form of skin cancer characterized by the uncontrolled growth of melanocytes, the pigment-producing cells in the skin. This condition is classified as 'in situ' because the cancerous cells are confined to the epidermis and have not invaded deeper tissues. The right lower eyelid is a critical area due to its proximity to the eye, and lesions here can affect both cosmetic appearance and ocular function. Diagnosis typically involves a biopsy, which confirms the presence of atypical melanocytes. Surveillance protocols for melanoma in situ include regular dermatological examinations, with a focus on monitoring for changes in the lesion's size, shape, or color. The risk of progression to invasive melanoma is a concern, particularly if the lesion is not adequately treated. Factors such as the patient's history of sun exposure, family history of skin cancer, and immunosuppression can influence the likelihood of progression. Treatment options often include surgical excision, and close follow-up is essential to ensure complete removal and to monitor for any new lesions.
Complete clinical notes including biopsy results, treatment plans, and follow-up care.
Diagnosis and management of melanoma in situ, including excisional biopsy and patient education.
Ensure accurate staging and documentation of the lesion's characteristics.
Detailed ocular examination findings and any impact on vision or ocular health.
Management of eyelid lesions and their implications for ocular function.
Coordination with dermatology for comprehensive care and monitoring.
Used when excising a melanoma in situ from the eyelid.
Document the size of the lesion, excised margins, and pathology results.
Ensure coordination between dermatology and ophthalmology for eyelid lesions.
Coding melanoma in situ accurately is crucial for treatment planning and monitoring progression. It helps in identifying patients at risk for invasive melanoma and ensures appropriate follow-up care.
